Product

Hikma introduces Respirox to the Tunisian market

February 2010, Hikma Pharmaceuticals introduces Respirox; the Atypical antipsychotic, to Tunisian market. The active ingredient Risperidone is one of the leading antipsychotics and has major role in the treatment of schizophrenia, bipolar disorder and agitation associated with autism.